Ceva appoints Joe Conti to Vice President, Regulatory Affairs – EPA and FDA

June 7, 2011, Lenexa, Kan. –– Ceva Animal Health is pleased to announce Joe Conti has been appointed Vice President, Regulatory Affairs for its North American Zone. Joe will report to Craig Wallace, CEO of Ceva’s North American Zone, and will serve on...

June 7, 2011, Lenexa, Kan. –– Ceva Animal Health is pleased to announce Joe Conti has been appointed Vice President, Regulatory Affairs for its North American Zone. Joe will report to Craig Wallace, CEO of Ceva’s North American Zone, and will serve on the North American Operations Committee.

 Craig said, “Joe brings tremendous experience, energy and insight to his new role. As we build our North American business, the foundation for that growth will be talent. We are fortunate to have professionals like Joe as part of our organization, and I am excited he is taking on these new responsibilities as we continue to expand and add new lines. Joe is a valuable member of our team, and I truly appreciate his dedication to product safety and regulatory affairs.”

Joe was a member of the original Summit VetPharm team, charged with the responsibility of registering three new products (Vectra for Dogs and Puppies, Vectra for Cats & Kittens, and Vectra 3D) from 2007 through 2009. He helped guide the new company through its formative years, eventually ascending to the role of Vice President, Regulatory and Development and serving on the management integration team when Ceva acquired Summit. His current responsibilities include all U.S., Canadian, state and local submissions, maintenance and enhancement of existing registrations, protocol development, testing and budgeting for EPA and FDA registrations and Pharmacovigilance. He is also integral in the assessment of existing products, development of new active ingredients and evaluation of new and novel application methods for both ecto- and endoparasiticides.

About Ceva Animal Health : Ceva’s key companion animal products include the Vectra® line of parasiticides, D.A.P.® and Feliway® pheromone behavior aids and Senilife® neuroprotection for aging pets.  Ceva Biomune’s key poultry products include CEVAC® Transmune IBD, Vectormune® FP and Vectormune® HVT.  Ceva Biomune Campus and the North America Zone headquarters are both located in Lenexa, Kansas.  Visit www.ceva.us.

About Ceva Santé Animale: Ceva’s parent company is a global veterinary health company focused on the research, development, production and marketing of pharmaceutical products and vaccines for pets, livestock, swine and poultry.  Its headquarters is in Libourne, France. Visit www.ceva.com.

For more information, please contact Carolyn Gilliland at carolyn.gilliland[at]ceva.com or 913.945.4448.

###

Back to top